Fig. 1.

Graphic representation of the variation in LDL-cholesterol levels during follow-up visits.

In all cases, the non-parametric Friedman test is used, as there was no normality in LDL levels in the time periods when the measurements were taken. This test was calculated for the first 18 months follow-up period with n = 56. According to this test, the LDL levels, for the two drugs separately and overall, fell significantly (p < 0.05) between month 0 (baseline) and the six-month follow-up, but then stabilised.

The table shows the number of patients (n) and the LDL-cholesterol levels recorded for each time period.